The company will be responsible for manufacturing and supply of an injectable anesthetic agent.
JHP president and CEO Stuart Hinchen said the company successfully completed an FDA (CBER) Pre-Approval Inspection in support of a biologic product launch for another long-term contract customer.
"Customers also rely on our extensive experience working with products throughout their life cycle which results in continuity of supply and program efficiencies," Hinchen added.